
EXACT SCIENCES

Answering Patients' Most Important Questions at Each Stage of Their Cancer Journey

Getting ahead of cancer is crucial no matter where people are in their cancer journey. From hereditary risk assessment and earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the cancer continuum. With a leading portfolio of products for earlier detection and treatment guidance, we help people face the most challenging decisions with confidence. To support these initiatives, Exact Sciences will continue to collaborate with health systems to ensure providers have timely access to test results and accessible support services such as result explanation and patient navigation programs.

Exact Sciences aims to be a partner for patients, providers, and health systems by creating solutions to unmet needs across the cancer care continuum, from screening to therapy selection. Exact Sciences is committed to continue changing the landscape of cancer care through innovation and collaborating with health systems like Mayo Clinic and Johns Hopkins to help people get the answers they need to make more informed decisions across the cancer continuum.

Innovating Across the Continuum to Elevate Cancer Care



*In development. Not all products are commercially available at this time.

PRECISION ONCOLOGY

Cologuard, Oncoguard, Riskguard and Exact Sciences are trademarks of Exact Sciences Corporation. Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, Oncotype DX Breast DCIS Score, DCIS Score, Oncotype DX Colon Recurrence Score, Colon Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. © 2023 Genomic Health, Inc. All rights reserved. M-US-ES-00862. January 2023